Novo Nordisk Loses GLP-1 Leadership to Eli Lilly
📊 NVO — Piyasa Yorumu
▼ down · 65%The headline indicates that Novo Nordisk has ceded its leadership in the GLP-1 market to Eli Lilly, increasing competitive pressure. Technical indicators also present a weak outlook, with the price trading below the SMA20 and SMA50, and the RSI at 37.6, nearing oversold territory. The MACD is in negative territory and below the signal line, confirming downward short-term momentum. The 4.16% decline over the last 24 hours suggests that selling pressure may persist in response to the news. However, since oversold conditions have not yet been established, the downside is likely to remain limited.
📊 LLY — Piyasa Yorumu
▲ up · 60%The headline indicates that Eli Lilly has overtaken Novo Nordisk in the GLP-1 market, which could positively impact the company's competitive strength. On the technical indicators, the RSI stands at 58, in neutral territory, while the MACD is negative but approaching its signal line, suggesting potential improvement in momentum. The price is above the SMA20 but below the SMA50, offering potential for a short-term recovery. A 1.4% increase over the last 24 hours reflects growing buyer interest. However, due to the SMA50 resistance and overall market uncertainties, the upside may remain limited.